ClinicalTrials.gg
CompletedNCT05245539Updated Dec 14, 2022

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

A Phase 1 interventional study of CVL-231 in Blood Pressure and Schizophrenia, sponsored by Cerevel Therapeutics, LLC. Completed at 10 sites in United States. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-12-14.

Sponsored by Cerevel Therapeutics, LLC (part of AbbVie) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
30 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Schizophrenia by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Schizophrenia · AbbVie.

Enrollment
18th of 27
151 · median 268
Started
2022
with 4 others
Phase 1
6 of 27
none open now
Registered
22nd of 27
by date

Among the 27 studies in Schizophrenia by AbbVie, this one is the 18th largest by enrollment, is one of 5 that started in 2022, is one of 6 in phase 1, and was the 22nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 27 studies in Schizophrenia by AbbVie is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 30 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Schizophrenia by AbbVie, or all of them as a file.
02

Study summary

The purpose of this trial is to characterize the effects of 2 oral doses (over 8 weeks total) of CVL-231 on ambulatory blood pressure and heart rate in patients with stable schizophrenia.

03

Conditions studied

  • Blood Pressure
  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants, ages 30 to 60 years, inclusive, at the time of signing the ICF.
  • Primary diagnosis of schizophrenia per , as confirmed by the MINI version 7.0.2.
  • PANSS Total Score ≤70 at the time of signing the ICF and Check-in (Day -5).

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis other than schizophrenia including, but not limited to, mental retardation; schizoaffective disorder; major depressive disorder; schizophreniform disorder; psychotic depression; bipolar disorder; post-traumatic stress disorder; generalized anxiety disorder, obsessive compulsive disorder, eating disorders (bulimia, anorexia), or other anxiety disorders as a primary diagnosis (Note: Anxiety symptoms secondary to schizophrenia are allowed); delirium, dementia, amnestic, or other cognitive disorders. Acute depressive symptoms within 30 days prior to signing the ICF that require treatment with an antidepressant are exclusory. Additional excluded conditions include borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  • Any of the following:

    • Schizophrenia considered resistant/ (defined as failure to respond to 2 or more courses of adequate pharmacological treatment) to antipsychotic treatment by history
    • History of failure to respond to clozapine
    • Response to clozapine treatment only
  • History of extrapyramidal symptoms treated with a medication that required dose modification and/or new treatment within 6 months prior to signing the ICF.
  • Current or past history of significant cardiovascular disease including any of the following: ischemic heart disease, myocardial infarction, cardiac valvulopathy, cardiac surgery revascularization (coronary artery bypass grafting) or stenting or percutaneous transluminal coronary angioplasty), hypertension, receiving medications to treat hypertension, orthostatic hypotension, angina, unstable angina, cerebrovascular accident or stroke or , pacemaker, atrial fibrillation, atrial flutter, paroxysmal atrial tachycardia, or non-sustained or sustained ventricular tachycardia, pulmonary arterial hypertension, sick sinus syndrome, Type 2 second-degree or third-degree atrioventricular block, congestive heart failure, personal or family history of sudden death or long syndrome, unexplained syncope or syncope within the last 3 years regardless of etiology.
  • 12-lead demonstrating any of the following at the Screening Visit or at Check-in (Day -5):

    • QTcF interval >450 ms
    • QRS interval >120 ms (unless right bundle branch block)
    • PR interval >200 ms
    • LVH with ST depressions and/or T wave inversions in leads with relatively tall R waves (ie, LVH with associated ST-T wave abnormalities)
    • Type 2 second-degree or third-degree atrioventricular block
    • Heart rate \<45 bpm or >90 bpm
    • Abnormal acute ECG changes (such as ST depression or elevation or T wave inversion)
    • Abnormal heart rhythm (atrial fibrillation and atrial flutter)
  • Blood pressure measurements demonstrating any of the following at the Screening Visit and at Check-in (Day -5):

    • Systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg

      o Blood pressure will be measured in a seated position after at least 3 minutes of rest. The average of 3 measurements will be used to determine eligibility.

    • Orthostatic hypotension, defined as a decrease of ≥20 mmHg in systolic blood pressure after at least 2 minutes of standing compared with the average of the resting supine blood pressure measurement
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    CVL-231 Dose Level 1

    10 mg once daily

    Drug: CVL-231

  • Experimental
    CVL-231 Dose Level 2

    30 mg once daily

    Drug: CVL-231

Interventions

  • CVL-231 is a brain penetrant mAChR activator that selectively binds to the M4 mAChR subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). CVL-231 is being developed for treatment of psychosis in schizophrenia.

06

What researchers measure

Primary outcomes

  1. Mean change from Baseline to Week 8 in the 24-hour ambulatory SBP (Systolic Blood Pressure)

    Time frame: Baseline to week 8

Secondary outcomes

  1. Mean changes from Baseline to Weeks 4 and 8 in ambulatory SBP during daytime period

    Time frame: At weeks 4 and 8

  2. Mean changes from Baseline to Weeks 4 and 8 in ambulatory SBP during nighttime period

    Time frame: At weeks 4 and 8

  3. Mean change from Baseline to Week 4 in the 24-hour ambulatory SBP

    Time frame: At week 4

  4. Mean change from Baseline to Weeks 4 and 8 in the 24-hour ambulatory DBP (Diastolic blood pressure)

    Time frame: At week 8

  5. Mean change from Baseline to Weeks 4 and 8 in the 24-hour ambulatory HR (Heart rate)

    Time frame: At weeks 4 and 8

  6. Number of treatment-emergent adverse events

    Time frame: Screening through day 84

  7. Frequency of clinically significant changes in electrocardiograms

    Time frame: Baseline through day 84

  8. Frequency of clinically significant changes in clinical laboratory assessments

    Time frame: Baseline through day 84

  9. Frequency of clinically significant changes in vital sign measurements

    Time frame: Baseline through day 84

  10. Frequency of clinically significant changes in physical examination results

    Time frame: Baseline through day 84

  11. Frequency of clinically significant changes in neurological examination results

    Time frame: Baseline through day 84

  12. Frequency of clinically significant findings in suicidality assessed using the C-SSRS (Columbia Suicide Severity Rating Scale)

    Time frame: Baseline through day 84

  13. Frequency of clinically significant findings in extrapyramidal symptoms evaluated using the SAS (Simpson Angus Scale)

    Time frame: Baseline through day 84

  14. Frequency of clinically significant findings in extrapyramidal symptoms evaluated using the AIMS (Abnormal Involuntary Movement Scale)

    Time frame: Baseline through day 84

  15. Frequency of clinically significant findings in extrapyramidal symptoms evaluated using the BARS (Barnes Akathisia Rating Scale)

    Time frame: Baseline through day 84

  16. Steady state CVL-231 Peak Plasma Concentration (Cmax) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Baseline through day 84

  17. Area under the plasma concentration-time curve over dosing interval (AUCτ) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Baseline through day 84

07

Study locations

10 sites
  • Pillar Clinical Research LLC
    Bentonville, Arkansas 72712, United States
  • Woodland International Research Group LLC - ERG - PPDS
    Little Rock, Arkansas 72211, United States
  • Collaborative NeuroScience Research, LLC - Torrance - Apex - PPDS
    Long Beach, California 90806, United States
  • Innovative Clinical Research, Inc - ClinEdge - PPDS
    Miami, Florida 33016, United States
  • Uptown Research Institute LLC
    Chicago, Illinois 60640, United States
  • Pillar Clinical Research LLC
    Lincolnwood, Illinois 60712, United States
  • Hassman Research Institute - Apex - PPDS
    Marlton, New Jersey 08053, United States
  • Neuro-Behavioral Clinical Research, Inc.
    North Canton, Ohio 44720, United States
  • Community Clinical Research
    Austin, Texas 78754, United States
  • Pillar Clinical Research LLC
    Richardson, Texas 75080, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Oct 2022, 8 months.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 8 months is below that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2022
First posted
Feb 18, 2022
StartActual
Jan 24, 2022
Primary completionActual
Oct 19, 2022
CompletionActual
Nov 14, 2022
Last update
Dec 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05245539
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
Jan 24, 2022
Primary completion
Oct 19, 2022
Completion
Nov 14, 2022
Last update
Dec 14, 2022

Study contacts

Erica Koenig, PhD
study director · Cerevel Therapeutics, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emraclidine

Start the discussion